Arab Finance: Net profits after tax of October Pharma jumped by 55.04% to EGP 143.835 million in the first half (H1) of 2026 from EGP 92.769 million in H1 2025, according to the financial results.
Earnings per share (EPS) climbed to EPG 11.99 in the first six months of 2026 from EGP 7.73 a year earlier, while revenues hiked to EGP 820.615 million from EGP 745.400 million.
In the first quarter (Q1) of 2026, October Pharma generated net profits after tax amounting to EGP 77.149 million, higher by 34.69% than EGP 57.279 million in Q1 2025.